1. Worldometers. COVID live: coronavirus statistics (2022) (Accessed 3 June 2022). www.worldometers.info/coronavirus/
Google Scholar
2. Rovina N, Koukaki E, Romanou V et al. Fungal infections in critically ill COVID-19 patients: inevitabile malum. J. Clin. Med. 11(7), 2017 (2022).
Medline CASGoogle Scholar
3. Fekkar A., Lampros A., Mayaux J et al. Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU. Am. J. Respir. Crit. Care Med. 203(3), 307–317 (2021).
Medline CASGoogle Scholar
4. WHO. Mucormycosis. www.who.int/southeastasia/outbreaks-and-emergencies/covid-19/What-can-we-do-to-keep-safe/mucormycosis
Google Scholar
5. Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia 186(6), 739–754 (2021).
Medline CASGoogle Scholar
6. Salehi M, Mahmoudi S, Rezahosseini O et al. The epidemiological, clinical, mycological, and pathological features of rhino-cerebral mucormycosis: a systematic review. Iran. J. Pathol. 17(2), 112–121 (2022).
MedlineGoogle Scholar
7. Bonifaz A, Tirado-Sánchez A, Hernández-Medel ML et al. Mucormycosis at a tertiary-care center in Mexico. A 35-year retrospective study of 214 cases. Mycoses 64(4), 372–380 (2021).
Medline CASGoogle Scholar
8. Walther G, Wagner L, Kurzai O. Updates on the taxonomy of Mucorales with an emphasis on clinically important taxa. J. Fungi (Basel) 5(4), 106 (2019).
Medline CASGoogle Scholar
9. Ibrahim AS, Kontoyiannis DP. Update on mucormycosis pathogenesis. Curr. Opin. Infect. Dis. 26(6), 508–515 (2013).
Medline CASGoogle Scholar
10. Pal R, Singh B, Bhadada SK et al. COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses 64(12), 1452–1459 (2021).
Medline CASGoogle Scholar
11. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J. Infect. 81(2), 266–275 (2020).
Medline CASGoogle Scholar
12. Palanisamy PR, Elango D. COVID-19 associated mucormycosis: a review. J. Family Med. Prim. Care 11(2), 418–423 (2022).
MedlineGoogle Scholar
13. Cornely OA, Alastruey-Izquierdo A, Arenz D et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 19(12), e405–e421 (2019).
Medline CASGoogle Scholar
14. Rudramurthy SM, Hoenigl M, Meis JF et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses 64(9), 1028–1037 (2021).
Medline CASGoogle Scholar
15. Sen M, Honavar SG, Bansal R et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), report 1. Indian J. Ophthalmol. 69(7), 1670–1692 (2021).
MedlineGoogle Scholar
16. Skaria J, John TM, Varkey S, Kontoyiannis DP. Are unique regional factors the missing link in India's COVID-19-associated mucormycosis crisis? mBio 13(2), e0047322 (2022).
MedlineGoogle Scholar
17. Hoenigl M, Seidel D, Carvalho A et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe 3(7), e543–e552 (2022).
Medline CASGoogle Scholar
18. Chakrabarti SS, Kaur U, Aggarwal SK et al. The pathogenetic dilemma of post-COVID-19 mucormycosis in India. Aging Dis. 13(1), 24–28 (2022).
MedlineGoogle Scholar
19. Stone N, Gupta N, Schwartz I. Mucormycosis: time to address this deadly fungal infection. Lancet Microbe 2(8), e343–e344 (2021).
MedlineGoogle Scholar

Vol. 18, No. 1

Metrics

Downloaded 55 times

History

Received 24 June 2022

Accepted 2 December 2022

Published online 17 January 2023

Published in print January 2023

Information

Keywords

Author contributions

A Bonifaz conceived and designed the work, drafted and critically revised the manuscript, reviewed the quality of the manuscript and accuracy of the work and approved the final version. A Tirado-Sánchez designed the work, drafted and critically revised the manuscript, reviewed the quality of the manuscript and accuracy of the work and approved the final version. J Araiza conceived the work, critically revised the manuscript, reviewed the quality of the manuscript and accuracy of the work and approved the final version. ML Hernández-Medel conceived and designed the work, critically revised the manuscript, reviewed the accuracy of the work and approved the final version.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Mucormycosis in the COVID-19 scenario beyond hospitalized patients

References